Bisphosphonates for postmenopausal osteoporosis

被引：122
|
作者：
Eastell, Richard [1 ]
Walsh, Jennifer S. [1 ]
Watts, Nelson B. [2 ]
Siris, Ethel [3 ]
机构：
[1] No Gen Hosp, Ctr Biomed Res, Natl Inst Hlth Res Biomed Res Unit Bone Dis, Sheffield S5 7AU, S Yorkshire, England
[2] Univ Cincinnati Bone Hlth & Osteoporosis Ctr, Cincinnati, OH USA
[3] Columbia Univ Med Ctr, Toni Stabile Osteoporosis Ctr, Dept Med, New York, NY USA
来源：
BONE | 2011年 / 49卷 / 01期
基金：
英国医学研究理事会;
关键词：
Osteoporosis; Alendronate; Ibandronate; Clodronate; Zoledronic acid; Risedronate; BONE-MINERAL DENSITY; INTRAVENOUS ZOLEDRONIC ACID; WEEKLY ORAL ALENDRONATE; VERTEBRAL FRACTURE RISK; RANDOMIZED-TRIAL; DOUBLE-BLIND; BIOCHEMICAL MARKERS; PARATHYROID-HORMONE; FEMORAL-NECK; WOMEN;
D O I：
10.1016/j.bone.2011.02.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Bisphosphonates are effective in reducing bone turnover, increasing BMD and reducing fracture risk in postmenopausal women with osteoporosis. The licensed bisphosphonates exhibit some differences in potency and speed of onset and offset of action. These differences mean that different agents may be more advantageous in different situations. Uncertainties still exist around the optimum duration of treatment and treatment holidays, how best to use bisphosphonates with anabolic treatments, and the benefits of treatment in patients who do not have a BMD T-score below -2.5. This article is part of a Special Issue entitled Bisphosphonates. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码：82 / 88
页数：7
相关论文
共 50 条
  • [1] Bisphosphonates for Postmenopausal Osteoporosis
    Ensrud, Kristine E.
    Crandall, Carolyn J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (20): : 2017 - 2018
  • [2] Intravenous bisphosphonates for postmenopausal osteoporosis
    Mottaghi, Peyman
    [J]. JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2010, 15 (03): : 175 - 184
  • [3] Bisphosphonates for prevention of postmenopausal osteoporosis
    Ravn, P
    [J]. DANISH MEDICAL BULLETIN, 2002, 49 (01) : 1 - 18
  • [4] The role of bisphosphonates in the prevention of postmenopausal osteoporosis
    Ambrosini, A
    Marchesoni, D
    Mozzanega, B
    [J]. WOMEN'S HEALTH IN THE 2000: FROM REPRODUCTION TO MENOPAUSE, 1999, : 133 - 140
  • [5] EFFICACY OF BISPHOSPHONATES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
    Galesanu, C.
    Lisnic, N.
    Mocanu, V.
    Florescu, A.
    Loghin, A-I
    Galesanu, M-R
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 : S739 - S739
  • [6] Drug insight: bisphosphonates for postmenopausal osteoporosis
    Chapurlat, RD
    Delmas, PD
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (04): : 211 - 219
  • [7] Injectable bisphosphonates in the treatment of postmenopausal osteoporosis
    Sartori, L
    Adami, S
    Filipponi, P
    Crepaldi, G
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2003, 15 (04) : 271 - 283
  • [8] Drug Insight: bisphosphonates for postmenopausal osteoporosis
    Roland D Chapurlat
    Pierre D Delmas
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 : 211 - 219
  • [9] Bisphosphonates for the treatment of postmenopausal osteoporosis: An update
    Cranney A.
    Adachi J.D.
    [J]. Clinical Reviews in Bone and Mineral Metabolism, 2007, 5 (3): : 145 - 152
  • [10] Injectable bisphosphonates in the treatment of postmenopausal osteoporosis
    Leonardo Sartori
    Silvano Adami
    Paolo Filipponi
    Gaetano Crepaldi
    [J]. Aging Clinical and Experimental Research, 2003, 15 (4) : 271 - 283
12345